Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the viral hepatitis market grown over the years?

The viral hepatitis market has experienced steady growth and is projected to rise from $16.21 billion in 2024 to $16.93 billion in 2025, reflecting a CAGR of 4.4%. Contributing factors include advancements in vaccine development, blood screening programs, antiviral drug availability, and global health initiatives.

What Is the forecasted market size and growth rate for the viral hepatitis market?

The viral hepatitis market is projected to grow steadily, reaching $19.97 billion by 2029, with a CAGR of 4.2%. Growth will be driven by better treatment accessibility, public health regulations, combination therapies, and health equity initiatives. Major trends include personalized treatment plans, the use of digital health tools, AI-driven disease monitoring, and hepatitis C micro-elimination efforts.

Get your viral hepatitis market report here!

https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report

What are the major factors driving growth in the viral hepatitis market?

The escalating incidence of hepatitis is predicted to drive the expansion of the viral hepatitis market. Hepatitis, an infection of the liver, can be triggered by a variety of infectious viruses and non-infectious substances leading to multiple health concerns. Viruses causing such a condition include Hepatitis A, B, C, D, and E, leading to inflammation and damage to the liver. For example, as per the European Centre for Disease Prevention and Control, a Sweden-based health agency, in April 2024, there were 28,855 recorded instances of hepatitis B virus infection across 30 EU/EEA Member States in 2022. This is a 78% increase from 16,187 cases in 2021. Furthermore, the case count in 2022, totaling 28,420, equates to a crude rate of 8.5 cases per 100,000 people. Hence, the escalating incidence of hepatitis will fuel the growth of the viral hepatitis market. The Viral Hepatitis Market is predicted to grow due to the surge in the amount of research and development activities in this field. The research and development aspect of viral hepatitis covers a wide spectrum of activities such as development of vaccines and antiviral medications, public health interventions, clinical trials, genomic research and epidemiological studies, among others. An uptick in these activities leads to treatment innovations, an increased range for diagnosis and prevention, an enhancement in global health initiatives, and increased competition amongst pharmaceuticals. As evidence, researchers in Melbourne, as per The Peter Doherty Institute for Infection and Immunity in Australia, procured $1.7 million in November 2022 for the forthcoming five years through the mRNA Victoria Activation Program to advance their groundbreaking work in finding a cure for hepatitis B virus infection. Consequently, the surge in the amount of research and development activities fuels the growth of the viral hepatitis market.

What key areas define the segmentation of the global viral hepatitis Market?

The viral hepatitis market covered in this report is segmented –

1) By Disease Type: Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types

2) By Diagnosis: Liver Biopsy, Blood Tests, Imaging Tests, Other Diagnosis

3) By Treatment: Antiviral Drugs, Surgery, Vaccine, Immune Modulator Drugs, Other Treatments

4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Hepatitis A: Acute Hepatitis A, Chronic Hepatitis A

2) By Hepatitis B: Acute Hepatitis B, Chronic Hepatitis B, Hepatitis B Carrier

3) By Hepatitis C: Acute Hepatitis C, Chronic Hepatitis C

4) By Other Disease Types: Hepatitis D, Hepatitis E

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13028&type=smp

What are the top market players propelling the growth of the viral hepatitis industry?

Major companies operating in the viral hepatitis market are Pfizer Inc., Johnson & Johnson Co, F Hoffmann-La Roche AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Hetero Drugs Ltd., Eisai Co. Ltd., Boehringer Ingelheim Group, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy’s Laboratories, Zydus Lifescience Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Otsuka Pharmaceutical Co. Ltd., Wockhardt Ltd.

What are the key trends shaping the future of the viral hepatitis market?

Firms in the viral hepatitis market are making strides in creating new medications and innovations to keep their industry standing. Enhancements in drug development and innovation provide scientific insights by offering a deeper understanding of disease mechanisms, thereby hastening the discovery of new treatments. For example, in November 2022, Gilead Sciences Inc., an American biopharmaceutical firm, reported that the FDA had given approval for the supplemental new drug application (sNDA) for Vemlidy (tenofovir alafenamide) 25 mg tablets. This is to be used as a daily treatment for chronic hepatitis B virus (HBV) infection in children aged 12 years and above who have compensated liver disease. Vemlidy’s approval in pediatric patients was backed by the results of a 24-week Phase 2 clinical trial.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13028

What regions are dominating the viral hepatitis market growth?

North America was the largest region in the viral hepatitis market in 2024. The regions covered in viral hepatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Human Papillomavirus (HPV) Vaccine Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/human-papillomavirus-hpv-vaccine-global-market-report

Liver Diseases Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Fatty Liver Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/fatty-liver-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: